Could a simple supplement boost rectal cancer treatment?
NCT ID NCT07239466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding a dietary supplement called β-hydroxybutyrate to a standard treatment plan (short-course radiotherapy, immunotherapy, and chemotherapy) can improve outcomes for people with locally advanced rectal cancer. The study will enroll 25 adults aged 18-75 who have not had prior treatment for their rectal cancer. The main goal is to see if this combination leads to a complete response, meaning no cancer is detectable after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
β-hydroxybutyrate (a dietary supplement) combined with short-course radiotherapy, immunotherapy, and chemotherapy (capecitabine and oxaliplatin)
What this could lead to
If successful, this could point toward a more effective neoadjuvant treatment for locally advanced rectal cancer, potentially increasing the chance of complete tumor disappearance before surgery.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The combination of treatments may cause side effects, and the supplement's benefit is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••